Cycl2r, you have identified an important tension in the

New Post Public Reply Private Reply Replies (1) Message Board
MGK_2 Cycl2R #163007
587
Cycl2r, you have identified an important tension in the CLOVER trial, and I'll answer it as completely as I can.
The short version: your concern is real, your logic is correct, and the fourth activity layer is directly relevant to resolving it, but not in isolation. The complete answer requires understanding what the TAS-102 backbone alone produces at RECIST, and what leronlimab's chemotherapy sensitization mechanism does to that number specifically.

The longer version follows.
The primary endpoint of CLOVER is objective response rate as defined by RECIST v1.1 criteria, in CCR5-positive, MSS, relapsed and refractory mCRC patients receiving leronlimab in combination with TAS-102 plus bevacizumab. You are correct that RECIST v1.1 ORR requires at least a 30 percent reduction in the sum of target lesion diameters to qualify as a partial response, and a complete disappearance to qualify as a complete response. 

ctDNA clearance, however dramatic, does not satisfy that criterion. The FDA adjudicates on RECIST. That is the published protocol and it does not flex for molecular response data alone. https://www.onclive.com/view/fda-approves-sac...ast-cancer  

So the question you are really asking is: what does the backbone produce at RECIST without leronlimab, and what does leronlimab's fourth activity layer contribute to that number?  About 2 years ago, I wrote about ORR: https://www.reddit.com/r/Livimmune/comments/1...e_changer/

The SUNLIGHT phase 3 trial answers the backbone question with precision. The ORR of patients treated with bevacizumab plus TAS-102 was 6.3 percent versus 0.9 percent for TAS-102 alone, with a disease control rate of 76.6 percent for the combination versus 47 percent for TAS-102 alone. This is the published benchmark for the standard of care backbone in this population. 

6.3 percent of patients on TAS-102 plus bevacizumab alone achieve RECIST-defined tumor shrinkage of at least 30 percent. The bar is low precisely because this population is heavily pretreated and the backbone's primary value is disease stabilization and overall survival extension, not tumor shrinkage. https://www.sciencedirect.com/science/article...2822000877  

This is where the fourth activity layer becomes directly relevant to your question, and not as a rescue but as the primary driver of RECIST response above the backbone baseline.

TAS-102 works by incorporating trifluridine into tumor cell DNA, causing DNA strand breaks and replication errors. Bevacizumab limits the tumor's ability to recruit new blood vessels to repair and sustain itself. Both mechanisms ultimately depend on the tumor cell's DNA damage response machinery to determine whether the cell dies or repairs and survives. 

The CCR5-dependent proliferative signaling cascade, specifically the CEP131, KHDRBS1, and MAPK6 cell cycle regulators whose activation is completely abolished by CCR5 knockout in the June 2026 Frontiers in Immunology phosphoproteomics paper, governs the tumor cell's ability to execute that repair response. When leronlimab blocks CCR5 simultaneously with TAS-102 delivering DNA damage, the tumor cell is facing strand breaks while its repair machinery is metabolically and biochemically compromised at the cell cycle level. The Seahorse metabolic profiling from the AACR Brain Cancer poster documented this directly: CCR5 inhibition reduced oxygen consumption rate in a dose-dependent manner, meaning the tumor cell's metabolic capacity to fuel the repair response is reduced at the same time the damage is being delivered.

This is the mechanical basis for expecting CLOVER's RECIST ORR to substantially exceed the 6.3 percent SUNLIGHT benchmark. Not because leronlimab independently kills tumor cells, but because it removes the metabolic and cell cycle infrastructure the tumor cell requires to survive TAS-102's DNA damage. More cells that would have repaired and survived the backbone chemotherapy instead die and meet RECIST response criteria.

The ctDNA picture adds a third layer of interpretive context. A median 70 percent ctDNA decline across evaluable CLOVER patients at week two, with four reaching completely undetectable levels, documents that tumor cell proliferative activity is being suppressed at the molecular level before the eight-week RECIST scan. Tumors in which circulating tumor DNA is declining sharply are tumors in which the replication machinery is being disrupted. Whether that disruption translates into enough cell death to produce 30 percent volumetric shrinkage measurable by CT imaging depends on the rate of cell death relative to the rate of residual stromal and fibrotic tissue contraction within the tumor mass. These are not always the same number, which is why ctDNA and RECIST can diverge. But a tumor in which ctDNA is collapsing at week two is a tumor in which the fourth activity layer is operating exactly as the framework would predict.

The confirmed ORR at ESMO in October will tell us how many patients crossed the 30 percent RECIST threshold. The molecular data says the mechanism is active. The RECIST scan says whether enough cells died fast enough to show up on imaging. Both questions have the same answer waiting in the same dataset. October is the moment both become visible simultaneously.

Your concern was precisely framed. The fourth activity layer is the direct mechanical answer to it, and the SUNLIGHT 6.3 percent baseline is the number it needs to exceed to demonstrate that leronlimab is doing something RECIST-meaningful to the backbone's cytotoxic capacity.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 92

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 94

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 52

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 28

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 71

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 89

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 81

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 101

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 43

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach

Updated Category News Views 67

A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...

Continue Reading

Top 5 Most Recently Viewed Articles

PAPZIMEOS Emerges as the Go-To Treatment for RRP Patients

Updated Category News Views 104

PAPZIMEOS: A Promising New Standard for RRP Therapy PAPZIMEOS (zopapogene imadenovec) has gained recognition as an innovative treatment for adults suffering from recurrent respiratory papillomatosis (RRP). This breakthrough comes following the publication of a consensus paper authored by 16 leading experts in the field. Sponsored by the Recurrent Respiratory...

Continue Reading
Ollie's Bargain Outlet Reports Encouraging Q2 Results

Updated Category News Views 159

Ollie's Bargain Outlet Achieves Strong Q2 Performance Ollie's Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) has made headlines recently as its shares experience fluctuations in the market. The company revealed impressive second-quarter adjusted earnings per share of 99 cents, surpassing analyst expectations of 94 cents. The quarterly sales reached $679.556 million, marking...

Continue Reading
Fivecast Introduces Groundbreaking Discovery Solution for OSINT

Updated Category News Views 184

Fivecast Unveils Discovery Solution to Combat Global Threats In today's rapidly evolving landscape of global threats, Fivecast, a prominent provider of advanced open-source intelligence (OSINT) solutions, has rolled out an innovative Discovery solution designed to assist analysts and investigators in both government and corporate settings. By elevating the speed and...

Continue Reading
Zen Technologies USA Advances Military Training with AI Simulations

Updated Category News Views 224

Zen Technologies USA Showcases Cutting-Edge AI Simulations Zen Technologies USA is set to revolutionize military training capabilities with its next-generation AI-enabled live and virtual simulation solutions. By enabling high-fidelity training for ground and naval forces, these innovations aim to accelerate the readiness of military units while significantly reducing...

Continue Reading
Sectra and Siemens Healthineers Transform Radiology Workflows

Updated Category News Views 494

Revolutionizing Radiology with Innovative Integrations International medical imaging IT and cybersecurity company Sectra (STO: SECT B) and Siemens Healthineers AG have formed a pivotal collaboration aimed at enhancing diagnostic capabilities in the radiology field. This initiative seeks to improve patient care by enabling seamless access to advanced imaging technologies....

Continue Reading